Biomarker Testing Services

Global Biomarker Testing Services Market to Reach US$1.1 Billion by 2030

The global market for Biomarker Testing Services estimated at US$700.5 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Biomarker Assay Development & Validation Service, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$762.6 Million by the end of the analysis period. Growth in the Flow Cytometry Service segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$184.1 Million While China is Forecast to Grow at 7.8% CAGR

The Biomarker Testing Services market in the U.S. is estimated at US$184.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$178.0 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Biomarker Testing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Testing Gaining Importance in Modern Healthcare?

Biomarker testing has become a cornerstone of precision medicine, enabling early disease detection, treatment monitoring, and patient stratification for targeted therapies. With the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, the need for reliable biomarker testing services has surged. These services facilitate more accurate diagnosis and treatment selection, ensuring better patient outcomes and reduced healthcare costs. The increasing reliance on biomarker-based diagnostics is also evident in the rapid expansion of personalized medicine. Pharmaceutical companies are integrating biomarker testing into drug development processes to identify patient populations that would benefit most from specific therapies. Additionally, regulatory agencies are mandating biomarker testing for companion diagnostics, ensuring drug efficacy and safety before market approval. As a result, healthcare providers and diagnostic laboratories are increasingly outsourcing biomarker testing services to specialized laboratories with advanced analytical capabilities.

How Are Technological Innovations Enhancing Biomarker Testing Services?

Technological advancements in genomics, proteomics, and bioinformatics are revolutionizing biomarker testing services, making them more precise, cost-effective, and accessible. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have improved the detection of genetic and molecular biomarkers, allowing for earlier disease identification and risk assessment. Additionally, the integration of artificial intelligence (AI) and machine learning in biomarker data analysis is optimizing test accuracy and accelerating result interpretation. The emergence of liquid biopsy techniques is another groundbreaking development in biomarker testing. These minimally invasive tests enable real-time monitoring of disease progression by analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Furthermore, advancements in multiplex biomarker assays allow for simultaneous testing of multiple biomarkers, reducing time and costs associated with traditional single-marker tests. As healthcare moves toward data-driven decision-making, these innovations are making biomarker testing services an indispensable tool in modern diagnostics and drug development.

What Market Trends Are Driving the Growth of Biomarker Testing Services?

The growing demand for early disease detection and personalized treatment plans is one of the key trends propelling the biomarker testing services market. Healthcare providers and researchers are prioritizing precision diagnostics to tailor treatments to individual patient profiles, leading to increased adoption of biomarker testing across various medical specialties. Oncology remains the largest application area, with biomarker-driven therapies playing a crucial role in immunotherapy, targeted cancer treatments, and chemotherapy response assessment. Another significant trend shaping the market is the rise of decentralized testing models. The shift toward home-based and point-of-care biomarker testing is being fueled by advances in telemedicine and remote patient monitoring technologies. Companies are developing portable biomarker testing kits and wearable biosensors to facilitate real-time health tracking, reducing the need for frequent hospital visits. Moreover, regulatory support for biomarker-driven clinical trials and drug approvals is encouraging pharmaceutical firms to integrate biomarker testing into their development pipelines, further boosting market demand.

What Are the Key Growth Drivers for the Biomarker Testing Services Market?

The growth in the Biomarker Testing Services market is driven by several factors including the rising incidence of chronic diseases, increasing adoption of precision medicine, and rapid technological advancements in biomarker detection methods. The expansion of companion diagnostics, which require biomarker testing for drug approval and patient selection, is further fueling market growth. Additionally, the increasing investment in clinical research and biotechnology innovations is expanding the scope of biomarker testing applications. Pharmaceutical companies are leveraging biomarker testing services to streamline drug development, reduce clinical trial failures, and enhance regulatory compliance. The shift toward non-invasive diagnostic techniques, such as liquid biopsy and multiplex biomarker panels, is also accelerating market expansion. As healthcare systems worldwide focus on improving diagnostic accuracy and treatment efficacy, biomarker testing services are expected to experience sustained growth, transforming the future of disease management and precision medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Testing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Service (Biomarker Assay Development & Validation Service, Flow Cytometry Service, Other Services); Type (Molecular Biomarkers, Cellular Biomarkers); End-Use (Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use, CROs End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 22 Featured) -

• ACM Global Laboratories
• BioAgilytix Labs, LLC
• Biomedica Medizinprodukte GmbH
• Charles River Laboratories, Inc.
• Creative Biolabs
• Discovery Life Sciences
• Frontage Laboratories, Inc.
• Intertek Group Plc
• Laboratory Corporation of America Holdings
• NorthEast BioLab
• Novigenix SA
• Pacific Biolabs
• Randox Laboratories Ltd.
• Raybiotech, Inc.
• Svar Life Science AB

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.